Allergic Rhinitis Due to Grass Pollens
5
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
20.0%
1 terminated out of 5 trials
80.0%
-6.5% vs benchmark
40%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis
Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen